Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

The South San Francisco, California-based biopharma company is developing genomic medicines for neurodegenerative diseases. In its lead program, Trace is developing an antisense oligonucleotide (ASO) ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Begin your TipRanks Premium journey today. Percheron Therapeutics (PERCF) Company Description: Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals.

Cbus Super CEO Kristian Fok is set to appear before the Senate Economics References Committee today in relation to a range of ...

In phase II and phase III, there are several compounds targeting tau, especially monoclonal antibodies (such as E2814, ...